Is thymus and activation-regulated chemokine a  forgotten diagnostic and minimal residual disease marker in classical Hodgkin lymphoma?

ConclusionReviewed studies suggest that TARC is one of the most promising markers, which can be used to improve treatment outcome in cHL.
Source: Memo - Magazine of European Medical Oncology - Category: Cancer & Oncology Source Type: research